Global healthcare major Johnson & Johnson on Friday said it has applied for Emergency Use Authorisation (EUA) of its single-dose COVID-19 vaccine in India. Earlier on Monday, the company had said that it remained committed to bringing its single-dose COVID-19 vaccine to India and looks forward to ongoing discussions with the Indian government.

Johnson & Johnson applies for vaccine authorisation in India

While the third-world countries are struggling to get coronavirus vaccine, a factory in the US ruined nearly 15 million doses of the Johnson & Johnson coronavirus vaccines

US: 15 million doses of Johnson & Johnson coronavirus vaccine destroyed

Johnson & Johnson Coronavirus vaccine has shown an overall 66% efficacy in preventing moderate to severe COVID-19. Although the trial results indicate that it is less effective against the virus variant first discovered in South Africa.

Single-dose Johnson & Johnson Coronavirus vaccine shows 66% efficacy